

CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS



BIO074B
March 2013

Jackson Highsmith
Project Analyst

ISBN: 1-56965-139-6

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports:
carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	3
INTENDED AUDIENCE	4
METHODOLOGY AND INFORMATION SOURCES	4
ANALYST'S CREDENTIALS	5
RELATED BCC REPORTS	5
BCC ON-LINE SERVICES	5
DISCLAIMER	6
CHAPTER 2 SUMMARY	8
<i>SUMMARY TABLE GLOBAL CNS BIOMARKER MARKET BY APPLICATION, THROUGH 2017 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL CNS BIOMARKER MARKET BY APPLICATION, 2010-2017 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	12
BIOMARKER DEFINITION	12
TYPES OF BIOMARKERS	13
HOW BIOMARKERS WORK	14
POTENTIAL BENEFITS OF USING BIOMARKERS	15
HISTORY	17
BIOMARKER DISCOVERY PROCESS	18
BIOMARKER IDENTIFICATION	18
Genetic Biomarkers	19
Transcriptional Biomarkers	20
Protein Indicating Biomarkers	20
Metabolic Biomarkers	20
BIOMARKER QUALIFICATION	20
BIOMARKER VERIFICATION	21
REGULATORY APPROVAL	21
<i>TABLE 1 FDA REGULATORY REQUIREMENTS FOR BIOMARKER DIAGNOSTIC TESTS</i>	22
BIOMARKERS AS DIAGNOSTIC TOOLS	22
SENSITIVITY AND SPECIFICITY	22
BIOMARKER ASSAY VALIDATION	23
QUALIFICATION OF BIOMARKER ASSAY	23
UTILIZATION ANALYSIS	24
Analytical Validation	24
Clinical Validation	24
Clinical Utility	24
CHAPTER 4 TECHNOLOGIES	26
GENOMICS	26
GENETIC BIOMARKERS	26

TOPIC	PAGE NO.
Genome-wide Association Scanning	27
Identification of SNPs	27
Examples of SNPs in Neurology	28
Limitations of SNPs	28
Transcriptional Biomarkers	29
TECHNOLOGY ADVANCEMENTS IN GENOMICS	30
Emerging Technologies in the Field of Genomics	31
RNA Interference	31
MicroRNA	31
EPIGENETICS	31
PROTEINS AND PROTEOMICS	32
PROTEIN ARRAYS AND OTHER PROTEIN TECHNOLOGIES	33
Functional Protein Array	33
Analytical Capture Array	33
Lysate Arrays	34
PROTEOMICS FOR NEUROLOGICAL DISEASES	34
METABOLOMICS	35
ADVANTAGES AND DISADVANTAGES OF VARIOUS BIOMARKER IDENTIFICATION TECHNOLOGIES	35
<i>TABLE 2 ADVANTAGES AND DISADVANTAGES OF EACH TECHNOLOGY FOR BIOMARKER STUDY</i>	36
DETECTION OF RNA	36
DETECTION OF DNA	37
PROTEIN EXPRESSION	37
SURROGATE BIOMARKERS OR COMPANION DIAGNOSTIC BIOMARKERS	37
<i>TABLE 3 COMPANION DIAGNOSTIC BIOMARKERS WITH FDA PMA APPROVAL</i>	39
<i>TABLE 4 EXAMPLES OF PHARMACEUTICAL/DIAGNOSTIC COMPANY PARTNERSHIPS TO DEVELOP COMPANION DIAGNOSTIC BIOMARKERS</i>	47
TECHNOLOGIES FOR BIOMARKER ANALYSIS: BIOINFORMATICS AND SUPERCOMPUTING	47
MOLECULAR IMAGING	48
Magnetic Resonance Imaging	49
MRI for Alzheimer's Disease	49
Diffusion Tensor MRI	49
Functional MRI	50
Positron Emission Tomography	50
Single Photon Emission Computed Tomography	51
CHAPTER 5 FACTORS INFLUENCING DEMAND FOR CNS BIOMARKERS	54
CHALLENGES IN FINDING EFFECTIVE TREATMENTS	54
SINGLE TARGET APPROACH	54
GENETIC ASSOCIATIONS	54
ANIMAL MODELS	54
CNS DISEASES ARE COMPLEX	55
INCREASE IN CHRONIC DISEASE AND INCREASING ACCESS TO HEALTH INSURANCE IN THE U.S.	56
LOW R&D PRODUCTIVITY IN THE BIOPHARMACEUTICAL INDUSTRY AND INCREASING COSTS OF CLINICAL TRIAL	57
UNMET NEEDS	58

TOPIC	PAGE NO.
FDA SUPPORT OF BIOMARKERS	58
NEURODEGENERATION AND NEUROLOGICAL DISORDERS	58
ALZHEIMER'S DISEASE	58
Gaps in Diagnosing AD	60
Biomarkers in Alzheimer's Disease	60
<i>TABLE 5 ESTABLISHED BIOMARKERS FOR ALZHEIMER'S DISEASE</i>	62
<i>TABLE 6 PREDICTIVE VALUE OF CURRENT AD BIOMARKERS</i>	63
Alzheimer's Treatments	63
Treatment for Mild to Moderate Alzheimer's	63
Treatment for Moderate to Severe Alzheimer's	64
PARKINSON'S DISEASE	64
GAPS IN TREATMENT	65
GAPS IN DIAGNOSIS	65
PARKINSON'S DISEASE BIOMARKERS	65
<i>TABLE 7 POTENTIAL BIOMARKERS FOR PARKINSON'S DISEASE</i>	66
MULTIPLE SCLEROSIS	68
PREVALENCE/INCIDENCE OF MS	68
GAPS IN TREATMENT	69
GAPS IN DIAGNOSING MULTIPLE SCLEROSIS	70
MULTIPLE SCLEROSIS BIOMARKERS	70
<i>TABLE 8 POTENTIAL BIOMARKERS FOR MULTIPLE SCLEROSIS</i>	71
AMYOTROPHIC LATERAL SCLEROSIS	72
GAPS IN TREATMENT AND DIAGNOSIS	72
<i>TABLE 9 ALS DRUGS IN CLINICAL TRIALS</i>	73
<i>TABLE 10 RECENT ALS DRUGS THAT FAILED IN PHASE III CLINICAL TRIALS</i>	74
ALS BIOMARKERS	74
<i>TABLE 11 POTENTIAL ALS BIOMARKERS</i>	74
<i>TABLE 12 PROTEINS IDENTIFIED IN NEXTGEN SCIENCES ASSAY 19-PLEX ALS TEST</i>	76
<i>TABLE 13 PROTEINS IDENTIFIED IN NEXTGEN SCIENCES' ASSAY 26-PLEX ALS TEST</i>	76
HUNTINGTON'S DISEASE	78
GAPS IN TREATMENT AND DIAGNOSIS	78
NEUROPSYCHIATRIC DISORDERS	78
ANXIETY DISORDERS	79
Panic Disorder	79
Obsessive-Compulsive Disorder	79
Social Anxiety Disorder (SAD)	79
Depression	80
TREATMENT GAPS FOR ANXIETY DISORDERS AND DEPRESSION	80
GAPS IN DIAGNOSIS	81
BIOMARKERS FOR DEPRESSION AND ANXIETY DISORDERS	81
Serotonin 2A Receptor Gene (HTR2A)	81
B-cell Lymphoma 2 Gene (Bcl-2)	81
Glutamate Receptor, Ionotropic Kainate 4 Gene (GRIK4)	81
SCHIZOPHRENIA	82
GAPS IN TREATMENT	82
GAPS IN DIAGNOSIS	82

TOPIC	PAGE NO.
BIOMARKERS FOR SCHIZOPHRENIA	83
<i>TABLE 14 MAJOR POTENTIAL BIOMARKERS FOR SCHIZOPHRENIA</i>	83
BIPOLAR DISORDER	84
BIPOLAR I DISORDER	84
BIPOLAR II DISORDER	84
CYCLOTHYMIACS DISORDER	84
GAPS IN TREATMENT AND DIAGNOSIS	84
BIPOLAR DISEASE BIOMARKERS	85
<i>TABLE 15 POTENTIAL BIOMARKERS FOR BIPOLAR DISEASE</i>	85
ATTENTION DEFICIT HYPERACTIVITY DISORDER	86
GAPS IN TREATMENT AND DIAGNOSIS	86
BIOMARKERS FOR ADHD	87
<i>TABLE 16 POTENTIAL BIOMARKERS FOR ADHD</i>	87
AUTISM	88
BIOMARKERS FOR AUTISM	88
GAPS IN TREATMENT AND DIAGNOSIS	88
CHAPTER 6 GLOBAL PHARMACEUTICAL MARKET	90
REGIONAL ANALYSIS OF THE GLOBAL PHARMACEUTICAL MARKET	90
<i>TABLE 17 GLOBAL PHARMACEUTICAL REVENUES, 2012 (\$ BILLIONS/%)</i>	90
<i>TABLE 18 PERCENTAGE OF DRUGS THAT ACHIEVE FDA APPROVAL BY DISEASE CATEGORY (%)</i>	91
PHARMACEUTICAL MARKETS IN CHINA AND INDIA	91
Pharmaceutical Market in China	91
Pharmaceutical Market in India	92
EMERGING PHARMACEUTICAL MARKETS	92
BRIC Countries	93
<i>TABLE 19 BRIC PHARMACEUTICAL REVENUES BY COUNTRY, THROUGH 2017 (\$ MILLIONS)</i>	93
Brazilian Pharmaceutical Market	93
Russian Pharmaceutical Market	94
Next 11 Market	94
ROLE OF GENOTYPING IN DRUG SUCCESS OR FAILURE	94
CHAPTER 7 CNS PHARMACEUTICAL AND BIOMARKER MARKETS	98
CNS PHARMACEUTICAL MARKET	98
<i>TABLE 20 ALZHEIMER'S SCHIZOPHRENIA AND DEPRESSION DRUGS IN CLINICAL TRIALS</i>	99
CNS BIOMARKER MARKET	99
<i>TABLE 21 GLOBAL CNS BIOMARKER MARKET BY APPLICATION, THROUGH 2017 (\$ MILLIONS)</i>	100
BIOMARKER DISCOVERY	101
Growth Drivers	101
Growth in Chronic Diseases	101
Favorable Funding Environment	101
Public-Private Partnerships	102
FNIH Biomarker Consortium	102
Alzheimer's Disease Neuroimaging Initiative (ADNI)	102

TOPIC	PAGE NO.
Predictive Safety Consortium	103
Growth Inhibitors	103
Lack of Short-Term Returns	103
Potential for Loss in Market Share	103
Lack of Standardized Methods	103
High Cost	103
BIOMARKERS IN DRUG DEVELOPMENT	104
Growth Drivers	104
Growth Inhibitors	104
MOLECULAR IMAGING AS BIOMARKER MODALITY	104
Growth Drivers	104
Growth Inhibitors	105
<i>TABLE 22 GLOBAL CNS BIOMARKER MARKET BY TECHNOLOGY, THROUGH 2017 (\$ MILLIONS)</i>	105
BIOMARKER DIAGNOSTIC TEST KITS	106
MAJOR PLAYERS IN THE CNS BIOMARKER DIAGNOSTIC MARKET	106
<i>TABLE 23 CNS DIAGNOSTICS COMPANIES AND DISEASE INDICATION</i>	107
<i>TABLE 24 CNS DIAGNOSTIC BIOMARKERS IN DEVELOPMENT BY INDICATION (NO.)</i>	108
GLOBAL CNS BIOMARKER MARKET BY REGION	108
<i>TABLE 25 GLOBAL CNS BIOMARKER MARKET BY REGION, 2010-2017 (\$ MILLIONS/%)</i>	109
CNS BIOMARKER REVENUES BY TECHNOLOGY	109
<i>TABLE 26 DISTRIBUTION OF REVENUES AMONG CNS DISEASES, 2012 (\$ MILLIONS/%)</i>	110
CHAPTER 8 CNS BIOMARKER PIPELINE	112
<i>TABLE 27 PERCENTAGE OF CNS REVENUE FROM EACH MAJOR CNS DISEASE SEGMENT AS OF 2012 (%)</i>	112
<i>TABLE 28 CNS DISEASE BIOMARKERS IN COMPANY PIPELINES</i>	113
CHAPTER 9 BIOMARKER INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS	116
INTRODUCTION	116
MAJOR MARKET DRIVERS	116
TECHNOLOGY	116
BUYERS	117
COMPETITION	117
IMPACT OF BIOMARKERS ON PHARMACEUTICAL INDUSTRY	118
IMPACT OF BIOMARKERS ON HEALTHCARE INDUSTRY	118
STRENGTHS, WEAKNESSES, OPPORTUNITIES AND THREATS (SWOT) ANALYSIS	118
<i>TABLE 29 SWOT ANALYSIS</i>	119
MOVING TOWARD PERSONALIZED MEDICINE	119
CHALLENGES TOWARD ADOPTION	120
BENEFITS OF PERSONALIZED MEDICINE	120
CHAPTER 10 CNS BIOMARKER CLINICAL TRIALS	123
<i>TABLE 30 CLINICAL TRIALS ON MAJOR CNS DISEASES (NO.)</i>	123
ONGOING CLINICAL TRIALS FOR MAJOR CNS DISEASES	123

TOPIC	PAGE NO.
<i>TABLE 31 ONGOING CLINICAL TRIALS ON DRUG BIOMARKERS IN MAJOR CNS DISEASES</i>	124
<i>TABLE 32 ONGOING CLINICAL TRIALS ON DIAGNOSTIC TEST BIOMARKERS IN MAJOR CNS DISEASES</i>	125
CLINICAL TRIALS ON CNS BIOMARKERS BEGINNING RECRUITMENT	126
<i>TABLE 33 CLINICAL TRIALS ON DRUG BIOMARKERS IN MAJOR CNS DISEASES BEGINNING RECRUITMENT</i>	126
<i>TABLE 34 CLINICAL TRIALS ON CNS DIAGNOSTIC BIOMARKER TESTS BEGINNING RECRUITMENT</i>	129
CHAPTER 11 PATENT ANALYSIS	133
U.S. PATENTS ISSUED FOR ALZHEIMER'S DISEASE BIOMARKERS	133
<i>TABLE 35 U.S. PATENTS ISSUED FOR ALZHEIMER'S DISEASE BIOMARKERS, 2009-2013</i>	133
U.S. PATENTS ISSUED FOR MULTIPLE SCLEROSIS BIOMARKERS	134
<i>TABLE 36 U.S. PATENTS ISSUED FOR MULTIPLE SCLEROSIS BIOMARKERS, 2012 TO JAN. 22, 2013</i>	134
U.S. PATENTS ISSUED FOR PARKINSON'S DISEASE BIOMARKERS	136
<i>TABLE 37 U.S. PATENTS ISSUED FOR PARKINSON'S DISEASE BIOMARKERS, 2008 TO FEB. 14, 2012</i>	136
U.S. PATENTS ISSUED FOR ALS DISEASE BIOMARKERS	137
<i>TABLE 38 U.S. PATENTS ISSUED FOR ALS DISEASE BIOMARKERS, 2012 TO JAN. 15, 2013</i>	137
WIPO PATENTS FOR BIOMARKERS AND ASSAYS FOR CNS DISEASES	138
<i>TABLE 39 WIPO PATENTS FOR BIOMARKERS AND ASSAYS FOR CNS DISEASES, 2011 TO JAN. 24, 2013</i>	139
<i>TABLE 40 NUMBER OF PATENT APPLICATIONS, 2012</i>	140
CHAPTER 12 MERGERS AND ACQUISITIONS, LICENSING AND PARTNERSHIP ACTIVITY IN 2012	142
MAJOR PHARMACEUTICAL BIOMARKER ACQUISITIONS	143
<i>TABLE 41 MAJOR PHARMACEUTICAL BIOMARKER TRANSACTIONS, 2012</i>	143
CHAPTER 13 COMPANY PROFILES	146
ABASTAR MDX INC.	146
ABIANT INC.	146
ACUMEN PHARMACEUTICALS INC.	147
ADLYFE INC.	147
ALSERES PHARMACEUTICALS INC.	148
APITOPE INTERNATIONAL	148
PRODUCTS	149
<i>TABLE 42 APITOPE PRODUCTS</i>	149
APOSENSE	149
APPLIED NEUROSOLUTIONS INC.	150
AVACTA GROUP PLC	150
CURIDIUM LTD.	150
AVID RADIOPHARMACEUTICALS INC.	151
BANYAN BIOMARKERS	151
DIAGENIC ASA	152

TOPIC	PAGE NO.
PRODUCTS	153
<i>TABLE 43 DIAGENIC PRODUCTS</i>	153
EXONHIT THERAPEUTICS	153
PRODUCTS	154
<i>TABLE 44 EXONHIT PRODUCTS</i>	154
GENENEWS LTD.	154
GLYCOMINDS LTD.	155
PRODUCTS	155
<i>TABLE 45 GLYCOMINDS PRODUCTS</i>	155
GREAT LAKES NEUROTECHNOLOGIES	155
INNOGENETICS BIOLOGICALS (SOLVAY SUBSIDIARY)	156
INNOVATIVE NEUROTECHNOLOGIES INC.	157
PRODUCTS	157
<i>TABLE 46 INNOVATIVE NEUROTECHNOLOGIES PRODUCTS</i>	157
MEMORY DX LLC (PREVIOUSLY PROVISTA LIFE SCIENCES)	157
METABOLON INC.	158
MYRIAD RBM INC.	159
OLIGOMERIX INC.	159
PRODUCTS	160
<i>TABLE 47 OLIGOMERIX PRODUCTS</i>	160
OPKO HEALTH INC.	160
OSTA BIOTECHNOLOGIES INC.	161
PRODUCTS	161
<i>TABLE 48 OSTA BIOTECHNOLOGIES' PRODUCT</i>	161
PROTEOME SCIENCES PLC	161
PRODUCTS	162
<i>TABLE 49 PROTEOME SCIENCES PRODUCTS</i>	162
PSYNOVA NEUROTECH LTD.	162
PXBIOVISION GMBH	163
RIDGE DIAGNOSTICS	163
PRODUCTS	164
<i>TABLE 50 RIDGE DIAGNOSTICS PRODUCTS</i>	164
SATORI PHARMACEUTICALS INC.	164
PRODUCTS	165
<i>TABLE 51 SATORI PHARMACEUTICALS PRODUCTS</i>	165
SABIOSCIENCES (SUBSIDIARY OF QIAGEN INC.)	165
PRODUCTS	166
<i>TABLE 52 SABIOSCIENCES CNS ASSAY PRODUCTS</i>	166
THERMO FISHER SCIENTIFIC (BRAHMS BIOMARKERS)	166

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL CNS BIOMARKER MARKET BY APPLICATION, THROUGH 2017 (\$ MILLIONS)	8
TABLE 1 FDA REGULATORY REQUIREMENTS FOR BIOMARKER DIAGNOSTIC TESTS	22
TABLE 2 ADVANTAGES AND DISADVANTAGES OF EACH TECHNOLOGY FOR BIOMARKER STUDY	36
TABLE 3 COMPANION DIAGNOSTIC BIOMARKERS WITH FDA PMA APPROVAL	39
TABLE 4 EXAMPLES OF PHARMACEUTICAL/DIAGNOSTIC COMPANY PARTNERSHIPS TO DEVELOP COMPANION DIAGNOSTIC BIOMARKERS	47
TABLE 5 ESTABLISHED BIOMARKERS FOR ALZHEIMER'S DISEASE	62
TABLE 6 PREDICTIVE VALUE OF CURRENT AD BIOMARKERS	63
TABLE 7 POTENTIAL BIOMARKERS FOR PARKINSON'S DISEASE	66
TABLE 8 POTENTIAL BIOMARKERS FOR MULTIPLE SCLEROSIS	71
TABLE 9 ALS DRUGS IN CLINICAL TRIALS	73
TABLE 10 RECENT ALS DRUGS THAT FAILED IN PHASE III CLINICAL TRIALS	74
TABLE 11 POTENTIAL ALS BIOMARKERS	74
TABLE 12 PROTEINS IDENTIFIED IN NEXTGEN SCIENCES ASSAY 19-PLEX ALS TEST	76
TABLE 13 PROTEINS IDENTIFIED IN NEXTGEN SCIENCES' ASSAY 26-PLEX ALS TEST	76
TABLE 14 MAJOR POTENTIAL BIOMARKERS FOR SCHIZOPHRENIA	83
TABLE 15 POTENTIAL BIOMARKERS FOR BIPOLAR DISEASE	85
TABLE 16 POTENTIAL BIOMARKERS FOR ADHD	87
TABLE 17 GLOBAL PHARMACEUTICAL REVENUES, 2012 (\$ BILLIONS/%)	90
TABLE 18 PERCENTAGE OF DRUGS THAT ACHIEVE FDA APPROVAL BY DISEASE CATEGORY (%)	91
TABLE 19 BRIC PHARMACEUTICAL REVENUES BY COUNTRY, THROUGH 2017 (\$ MILLIONS)	93
TABLE 20 ALZHEIMER'S SCHIZOPHRENIA AND DEPRESSION DRUGS IN CLINICAL TRIALS	99
TABLE 21 GLOBAL CNS BIOMARKER MARKET BY APPLICATION, THROUGH 2017 (\$ MILLIONS)	100
TABLE 22 GLOBAL CNS BIOMARKER MARKET BY TECHNOLOGY, THROUGH 2017 (\$ MILLIONS)	105
TABLE 23 CNS DIAGNOSTICS COMPANIES AND DISEASE INDICATION	107
TABLE 24 CNS DIAGNOSTIC BIOMARKERS IN DEVELOPMENT BY INDICATION (NO.)	108
TABLE 25 GLOBAL CNS BIOMARKER MARKET BY REGION, 2010-2017 (\$ MILLIONS/%)	109
TABLE 26 DISTRIBUTION OF REVENUES AMONG CNS DISEASES, 2012 (\$ MILLIONS/%)	110
TABLE 27 PERCENTAGE OF CNS REVENUE FROM EACH MAJOR CNS DISEASE SEGMENT AS OF 2012 (%)	112
TABLE 28 CNS DISEASE BIOMARKERS IN COMPANY PIPELINES	113
TABLE 29 SWOT ANALYSIS	119
TABLE 30 CLINICAL TRIALS ON MAJOR CNS DISEASES (NO.)	123
TABLE 31 ONGOING CLINICAL TRIALS ON DRUG BIOMARKERS IN MAJOR CNS DISEASES	124
TABLE 32 ONGOING CLINICAL TRIALS ON DIAGNOSTIC TEST BIOMARKERS IN MAJOR CNS DISEASES	125

TABLE HEADING	PAGE NO.
TABLE 33 CLINICAL TRIALS ON DRUG BIOMARKERS IN MAJOR CNS DISEASES BEGINNING RECRUITMENT	126
TABLE 34 CLINICAL TRIALS ON CNS DIAGNOSTIC BIOMARKER TESTS BEGINNING RECRUITMENT	129
TABLE 35 U.S. PATENTS ISSUED FOR ALZHEIMER'S DISEASE BIOMARKERS, 2009-2013	133
TABLE 36 U.S. PATENTS ISSUED FOR MULTIPLE SCLEROSIS BIOMARKERS, 2012 TO JAN. 22, 2013	134
TABLE 37 U.S. PATENTS ISSUED FOR PARKINSON'S DISEASE BIOMARKERS, 2008 TO FEB. 14, 2012	136
TABLE 38 U.S. PATENTS ISSUED FOR ALS DISEASE BIOMARKERS, 2012 TO JAN. 15, 2013	137
TABLE 39 WIPO PATENTS FOR BIOMARKERS AND ASSAYS FOR CNS DISEASES, 2011 TO JAN. 24, 2013	139
TABLE 40 NUMBER OF PATENT APPLICATIONS, 2012	140
TABLE 41 MAJOR PHARMACEUTICAL BIOMARKER TRANSACTIONS, 2012	143
TABLE 42 APIOTOPE PRODUCTS	149
TABLE 43 DIAGENIC PRODUCTS	153
TABLE 44 EXONHIT PRODUCTS	154
TABLE 45 GLYCOMINDS PRODUCTS	155
TABLE 46 INNOVATIVE NEUROTECHNOLOGIES PRODUCTS	157
TABLE 47 OLIGOMERIX PRODUCTS	160
TABLE 48 OSTA BIOTECHNOLOGIES' PRODUCT	161
TABLE 49 PROTEOME SCIENCES PRODUCTS	162
TABLE 50 RIDGE DIAGNOSTICS PRODUCTS	164
TABLE 51 SATORI PHARMACEUTICALS PRODUCTS	165
TABLE 52 SABIOSCIENCES CNS ASSAY PRODUCTS	166

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL CNS BIOMARKER MARKET BY APPLICATION, 2010-2017 (\$ MILLIONS)	8